74 | A MULTICENTER PHASE II STUDY OF GLOFITAMAB PLUS POLATUZUMAB‐R‐CHP FOR PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA
Jennifer L. Crombie(Dana-Farber Cancer Institute), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Robert Redd(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Oreofe O. Odejide(Dana-Farber Cancer Institute), Michael Forsyth(Dana-Farber Cancer Institute), R. Merryman(Dana-Farber Cancer Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Gottfried von Keudell(Beth Israel Deaconess Medical Center), Philippe Armand(Harvard University), Inhye E. Ahn(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Eileen Parry(European Organisation for Research and Treatment of Cancer), Michele Stanchina(Sylvester Comprehensive Cancer Center), Christine E. Ryan(Dana-Farber Cancer Institute), A. I. Kim(Dana-Farber Cancer Institute), Eric D. Jacobsen(Dana-Farber Cancer Institute), David Qualls(Memorial Sloan Kettering Cancer Center), Ann S. LaCasce(Otsuka (Japan)), Alvaro J. Alencar(University of Miami), David C. Fisher(Dana-Farber Cancer Institute), Craig H. Moskowitz(University of Miami), Sandra Re(Bristol-Myers Squibb (United States)), Chris Carey(University of Brighton)
Cited by 3
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k